Underutilization of therapy for hepatocellular carcinoma in the medicare population

Cancer

Volumn 117, Issue 5, 2011, Pages 1019-1026

  Shah, Shimul A ^a   Smith, Jillian K ^a   Li, YouFu ^a   Ng, Sing Chau ^a   Carroll, James E ^a   Tseng, Jennifer F ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

And end results (SEER); Epidemiology; Hepatocellular carcinoma; Liver transplantation; Medicare; Surveillance; Use

Indexed keywords

ABLATION THERAPY; AGED; ARTICLE; ASIAN; CANCER INCIDENCE; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEGRO; OVERALL SURVIVAL; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MEDICARE; PHYSICIAN'S PRACTICE PATTERNS; POPULATION; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 79952021851     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25683     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
2. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340: 745-750. (Pubitemid 29114292)
3. Akriviadis EA, Llovet JM, Efremidis SC, et al. Hepatocellular carcinoma. Br J Surg. 1998;85:1319-1331. (Pubitemid 28468331)
4. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942-1956.
5. Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol. 2003;39(suppl 1):S59-S63. (Pubitemid 37222648)
6. Shah SA, Cleary SP, Tan JC, et al. An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. Ann Surg Oncol. 2007;14:2608-2614. (Pubitemid 47389575)
7. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576. (Pubitemid 46890874)
8. El Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158-166. (Pubitemid 41772530)
9. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40:IV-IV-61-55-IV-61.
10. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-IV-18-3-IV-18.
11. Murphy MM, Simons JP, Hill JS, et al. Pancreatic resection: a key component to reducing racial disparities in pancreatic adenocarcinoma. Cancer. 2009;115:3979-3990.
12. Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, Tseng JF. Progress for resectable cancer?: a population-based assessment of US practices. Cancer. 2010;116:1681-1690.
13. Li B, Evans D, Faris P, Dean S, Quan H. Risk adjustment performance of Charlson and Elixhauser comorbidities in ICD-9 and ICD-10 administrative databases. BMC Health Serv Res. 2008;8:12.
14. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
15. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267. (Pubitemid 32007842)
16. El Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33:62-65.
17. Davila JA, Petersena NJ, Nelson HA, El Serag HB. Geographic variation within the United States in the incidence of hepatocellular carcinoma. J Clin Epidemiol. 2003;56:487-493. (Pubitemid 36694102)
18. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856. (Pubitemid 43980480)
19. Hassan MM, Frome A, Patt YZ, El Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2002;35:266-269. (Pubitemid 34913096)
20. Amin J, Dore GJ, O'Connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol. 2006;45:197-203.
21. Nguyen GC, Segev DL, Thuluvath PJ. Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol. 2007;5:1092-1099.
22. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care. 2005;11 (10 suppl):S286-S295. (Pubitemid 41552219)
23. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89-99.
24. Shah SA, Cleary SP, Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141:330-339. (Pubitemid 46371307)
25. Pawlik TM, Esnaola NF, Vauthey JN. Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. Liver Transpl. 2004;10(2 suppl 1): S74-S80. (Pubitemid 38240105)
26. Llovet JM, Sala M. Non-surgical therapies of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2005;17: 505-513. (Pubitemid 40592707)
27. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699. (Pubitemid 26079803)
28. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500-507. (Pubitemid 30640096)
29. Davila JA, El Serag HB. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol. 2006;4:104-110. (Pubitemid 43129531)
30. Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006;106:1276-1285. (Pubitemid 43363904)
31. Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116:1367-1377.
32. Davila JA, Weston A, Smalley W, El Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007;41:777-782. (Pubitemid 47267765)
33. El Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37(suppl 2):S88-S94.